Abstract:Recent advances have driven the development of immunotherapies that act by either promoting or suppressing a patient’s immune system to treat inflammation, autoimmune disease, cardiovascular disease, infectious diseases, and several cancers. In addition, research conducted over the past 25 years has identified therapeutic targets and indicated that immunotherapy could be used to treat Alzheimer’s disease (AD). Despite a number of setbacks, this approach has now led to the development of the first disease-modifying treatments for this devastating disease. A key neuropathological feature of AD is the accumulation of a ~40-amino acid peptide known as amyloid β (Aβ) in the brain and cerebrovasculature. Our detection of an Aβ precursor protein mutation that caused early-onset AD in a Swedish family by enhancing Aβ protofibril formation sharpened the focus on soluble Aβ aggregates (oligomers and protofibrils) as viable therapeutic targets. Initial studies developed and tested a mouse monoclonal antibody (mAb158) with specific conformation-dependent binding to these soluble Aβ aggregates. Treatment with mAb158 selectively reduced Aβ protofibrils in the brain and cerebrospinal fluid of a transgenic mouse model of AD. A humanized version of mAb158 (lecanemab) subsequently entered clinical trials. Based on promising Phase 2 data showing plaque clearance and reduced cognitive decline, a Phase 3 trial found that lecanemab slowed decline on the primary cognitive endpoint by 27% over 18 months and also produced positive effects on secondary clinical endpoints and key biomarkers. In July 2023, the FDA granted lecanemab a full approval, and this therapeutic antibody will be marketed as Leqembi®. This represents a significant advance for patients with AD, although many challenges remain. In particular, it is now more important than ever to identify individuals who are vulnerable to AD, so that treatment can be initiated at an early stage in the disease process.

Can Targeted Protein Degradation Technology Provide a Potential Breakthrough in the Development of Anti-AD Drugs?

Recent Advances: Decoding Alzheimer’s Disease with Stem Cells

Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns

Targeting protein kinases for the treatment of Alzheimer's disease: Recent progress and future perspectives

Advances in Alzheimer's Disease-Associated Aβ Therapy Based on Peptide

Harnessing the Therapeutic Potential of Peptides for Synergistic Treatment of Alzheimer's Disease by Targeting Aβ Aggregation, Metal-Mediated Aβ Aggregation, Cholinesterase, Tau Degradation, and Oxidative Stress

Amyloid-β in Alzheimer's disease: Structure, toxicity, distribution, treatment, and prospects

Immunotherapy for Alzheimer's Disease: Targeting Β-Amyloid and Beyond.

Amyloid-Directed Antibodies: Past, Present, and Future

Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies

Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond

A light at the end of the tunnel - from mutation identification to a potential treatment for Alzheimer's disease

Advancements in Pharmacological Treatment of Alzheimer's Disease: The Advent of Disease-Modifying Therapies (DMTs)

Recent advances in targeted protein degraders as potential therapeutic agents

Innovative Therapeutic Strategies in Alzheimer's Disease: A Synergistic Approach to Neurodegenerative Disorders

Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics

Versatile nanomaterials for Alzheimer's disease: Pathogenesis inspired disease-modifying therapy

A light at the end of the tunnel – from mutation identification to a potential treatment for Alzheimer’s disease

Cutting Edge Research on Drug Treatment Strategies and Emerging Therapies for Alzheimer’s Disease

Progress in Target Drug Molecules for Alzheimer's Disease.

Targeted protein degradation in drug development: Recent advances and future challenges